PLRZ Latest Press Releases

-- October 27, 2026 --

Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker Globe Newswire 8:16 AM

-- October 5, 2026 --

Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform Globe Newswire 7:32 AM

-- September 22, 2026 --

Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker Globe Newswire 8:33 AM

-- September 4, 2026 --

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement Globe Newswire 11:58 AM

-- September 3, 2026 --

Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement Globe Newswire 8:50 AM

-- September 2, 2026 --

Polyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study Globe Newswire 7:32 AM

-- August 20, 2026 --

Polyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment Globe Newswire 9:30 AM

-- July 2, 2026 --

Polyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial Globe Newswire 7:32 AM

-- June 29, 2026 --

Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial Globe Newswire 8:44 AM

-- June 17, 2026 --

Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform Globe Newswire 8:15 AM

-- June 15, 2026 --

Polyrizon Advances NASARIX Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway Globe Newswire 8:05 AM

-- June 10, 2026 --

Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology Globe Newswire 7:47 AM

-- June 8, 2026 --

Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX Trial Globe Newswire 9:25 AM

Market Data Delayed 15 Minutes